- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT03772002
Hepatitis C Surveillance With Linkage to Care of Patients From Non-ID Departments in Jiangsu
Hepatitis C Surveillance With Linkage to Care of Patients From Non-infectious Departments in Tertiary Hospitals From Jiangsu, China
Due to the occult nature of hepatitis C virus (HCV), it is estimated that less than 5% of people with chronic hepatitis C (CHC) infection knowing their status. The major challenges are that awareness is lacking, reliable diagnostics and testing services are not sufficiently available, and laboratory capacity is weak. In the context of major tertiary hospitals, the well-functioning laboratories would ensure the high-quality HCV testing, which facilitate the identification of inpatients who are unaware of HCV infection. However, given the preliminary data, diagnostic rate of inpatients from non-infectious (non-ID) departments is disturbingly low. A recent study from a major hospital in Jilin province of China showed that 3.36% of inpatients were anti-HCV positive; however, HCV RNA confirmatory testing was not further performed in this study.
From the retrospective cohort in non-ID departments of a tertiary hospital of Jiangsu during 2016 to 2017, only 25.9% (71/273) of patients with anti-HCV antibody (Ab) further had HCV RNA confirmatory test, while 40% (29/71) were identified as CHC. The previous data indicates that insufficient anti-HCV Ab testing and insufficient follow-up of patients with positive anti-HCV Ab from non-ID departments. Indeed, compared to hospitals in Western countries, the infectious department in Chinese hospitals are relative independent from non-ID departments, meanwhile the knowledge of HCV infection is relatively lacking for non-ID physicians. Therefore, an appropriate clinical pathway for integration and linkage of non-ID department and ID departments for diagnosis and care delivery of CHC patients is urgently needed. The investigator aim to establish a feasible clinical pathway and consensus guideline to enhance HCV testing surveillance with linkage to care in non-ID departments. Moreover, the participants with anti-HCV Ab also will be enrolled in the HCV prospective cohort, in which the intervention and clinical outcome of hepatitis will be longitudinally monitored in the future study.
연구 개요
연구 유형
등록 (예상)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Jiangsu
-
Changzhou, Jiangsu, 중국, 213001
- The Third Hospital of Changzhou
-
Nanjing, Jiangsu, 중국, 210008
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Retrospective cohort:
- ≥ 18 years of age.
- Inpatients from non-infectious department.
- Documentation of laboratory test indicating positive HCV antibody.
Prospective cohort:
- ≥ 18 years of age.
- Inpatients from non-infectious departments.
Patients who meet the requirement of HCV antibody screening:
- patients with high risk possibility of HCV infection.
- patients who will have special or invasive medical operation.
- patients with unexplained abnormal liver biochemical laboratory results.
Exclusion Criteria:
Retrospective cohort: Duplicated subjects.
Prospective cohort:Inability or unwillingness to provide informed consent or abide by the requirements of the study.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 상영
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: HCV screening
|
HCV antibody and HCV RNA surveillance, anti-HCV treatment assessment
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
The percentage of patients in non-infectious departments who had positive HCV antibody testing but failed to get HCV RNA test.
기간: 1 years
|
1 years
|
The percentage of HCV-RNA positivity among patients with the presence of anti-HCV antibody in non-infectious departments after Non-ID HCV screening.
기간: 1 years
|
1 years
|
The percentage of HCV-RNA positivity linkage to care consensus guideline shaped.
기간: 1 years
|
1 years
|
2차 결과 측정
결과 측정 |
기간 |
---|---|
The percentage of CHC patients linked to care in non-infectious departments.
기간: 1 years
|
1 years
|
The treatment timeliness as embodied as time period from diagnosis to engagement to anti-HCV DAA treatment.
기간: 1 years
|
1 years
|
The referral rate of identified HCV infected patients.
기간: 1 years
|
1 years
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (예상)
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- IN-CN-987-5343
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
만성 C형 간염에 대한 임상 시험
-
Hospital Clinic of BarcelonaAstraZeneca완전한CTO(Chronic Total Occlusion)를 위한 PCI(Percutaneous Coronary Intervention)를 받을 예정인 환자스페인
-
Meir Medical Center완전한디지털 스테레오 광 디스크 이미지에서 C/D 비율을 측정하는 새로운 기술 개발 | C/D 측정의 관찰자 내 재현성 | C/D 측정의 관찰자 간 가변성
-
University Hospital, GrenobleClinical Investigation Centre for Innovative Technology Network완전한
-
Haisco Pharmaceutical Group Co., Ltd.완전한
-
University Hospital, Caen완전한
-
University of Sao Paulo General HospitalInCor Heart Institute; Chinese Academy of Medical Sciences, Fuwai Hospital; Beneficência... 그리고 다른 협력자들알려지지 않은
HCV screening에 대한 임상 시험
-
ANRS, Emerging Infectious DiseasesInstitut National de la Santé Et de la Recherche Médicale, France; Fondation Mérieux; University... 그리고 다른 협력자들알려지지 않은
-
Fundacion para la Investigacion Biomedica del Hospital...Instituto de Salud Carlos III완전한
-
H. Lee Moffitt Cancer Center and Research Institute완전한
-
Asociacion para el Estudio del HigadoMerck Sharp & Dohme LLC알려지지 않은
-
Denver Health and Hospital AuthorityBoston University; Johns Hopkins University; Boston Medical Center; University of Cincinnati; University of Mississippi Medical Center 그리고 다른 협력자들모집하지 않고 적극적으로
-
Foundation for Innovative New Diagnostics, Switzerland완전한